Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Research & Development (2016 - 2025)

Historic Research & Development for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to $2.1 million.

  • Lifecore Biomedical, Inc. \De\'s Research & Development fell 268.39% to $2.1 million in Q2 2025 from the same period last year, while for May 2025 it was $8.3 million, marking a year-over-year decrease of 369.68%. This contributed to the annual value of $8.3 million for FY2025, which is 369.68% down from last year.
  • According to the latest figures from Q2 2025, Lifecore Biomedical, Inc. \De\'s Research & Development is $2.1 million, which was down 268.39% from $2.0 million recorded in Q1 2025.
  • Lifecore Biomedical, Inc. \De\'s 5-year Research & Development high stood at $2.3 million for Q1 2022, and its period low was $1.6 million during Q1 2021.
  • For the 5-year period, Lifecore Biomedical, Inc. \De\'s Research & Development averaged around $2.0 million, with its median value being $2.1 million (2023).
  • The largest annual percentage gain for Lifecore Biomedical, Inc. \De\'s Research & Development in the last 5 years was 31250.0% (2021), contrasted with its biggest fall of 4040.77% (2021).
  • Quarter analysis of 5 years shows Lifecore Biomedical, Inc. \De\'s Research & Development stood at $1.7 million in 2021, then rose by 29.58% to $2.2 million in 2022, then dropped by 3.63% to $2.1 million in 2023, then dropped by 8.29% to $1.9 million in 2024, then increased by 9.3% to $2.1 million in 2025.
  • Its Research & Development stands at $2.1 million for Q2 2025, versus $2.0 million for Q1 2025 and $1.9 million for Q4 2024.